bimekizumab · Bimzelx

Monoclonal antibody

Also known as UCB4940

Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis (label: moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or...), Psoriatic Arthritis, Hidradenitis Suppurativa

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (5)
US
  • Non-Radiographic Axial Spondyloarthritis BIMZELX is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.
  • Ankylosing Spondylitis BIMZELX is indicated for the treatment of adults with active ankylosing spondylitis.Outside this platform's coverage
Product first approved 2023FDA label
CA
  • Bimzelx (bimekizumab injection) is indicated for: • Psoriasis (PsO) The treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. • Psoriatic arthritis (PsA) The treatment of adult patients with active psoriatic arthritis. Bimzelx can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate). • Axial Spondyloarthritis (axSpA) Ankylosing Spondylitis (AS, radiographic spondyloarthritis) The treatment of adult patients with active ankylosing spondylitis...
Product first approved 2022Health Canada
JP
  • Plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma in patients not sufficiently responding to existing treatments (UCB release dated 2022-01-24)
Product first approved 2022ucb.com
EU
  • Moderate-to-severe plaque psoriasis in adults (first indication); current label includes PsA, axSpA and hidradenitis suppurativa
Product first approved 2021EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (25)
Hidradenitis Suppurativa
NCT06921850 · UCB Biopharma SRL
2025-04-07 – 2029-03-06 · Hidradenitis Suppurativa
What this study did
NCT04901195 · UCB Biopharma SRL
2021-05-27 – 2026-07-22 · Hidradenitis Suppurativa
What this study did
Psoriasis
NCT06425549 · UCB Biopharma SRL
2024-06-25 – 2030-11-08 · Moderate to Severe Plaque Psoriasis
What this study did
NCT07836283 · University Hospital, Rouen
2026-10-15 – 2030-10-15 · Axial or Predominantly Axial SpondyloArthritis With or Without Psoriasis
What this study did
NCT06011733 · UCB Biopharma SRL
2023-10-31 – 2025-02-05 · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
What this study did
NCT03598790 · UCB Biopharma SRL
2018-09-05 – 2023-11-14 · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
What this study did
NCT03536884 · UCB Biopharma SRL
2018-06-13 – 2023-08-09 · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
What this study did
NCT05020249 · UCB Biopharma SRL
2021-09-27 – 2022-09-06 · Moderate to Severe Plaque Psoriasis
What this study did
NCT03766685 · UCB Biopharma SRL
2018-12-20 – 2020-09-08 · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT06506916 · UCB Biopharma SRL
2024-07-29 – 2028-03-14 · Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
What this study did
NCT04009499 · UCB Biopharma SRL
2019-08-13 – 2026-05-26 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT07219420 · UCB Biopharma SRL
2025-11-14 – 2029-11-22 · Palmoplantar Pustulosis
What this study did
NCT04436640 · UCB Biopharma SRL
2020-06-16 – 2026-08-09 · Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
What this study did
NCT03928704 · UCB Biopharma SRL
2019-04-25 – 2023-04-17 · Nonradiographic Axial Spondyloarthritis
What this study did
NCT03928743 · UCB Biopharma SRL
2019-04-25 – 2022-08-08 · Ankylosing Spondylitis
What this study did
Phase 2 (14)
Hidradenitis Suppurativa
NCT03248531 · UCB Biopharma SRL
2017-09-22 – 2019-02-21 · Hidradenitis Suppurativa
What this study did
Psoriasis
NCT06742333 · Centre Hospitalier Universitaire de Nice
2025-07-22 – 2029-01-01 · Psoriasis
What this study did
NCT04718896 · UCB Biopharma SRL
2021-04-06 – 2025-03-12 · Moderate to Severe Plaque Psoriasis
What this study did
NCT03230292 · UCB Biopharma SRL
2017-07-03 – 2019-03-06 · Chronic Plaque Psoriasis
What this study did
NCT03010527 · UCB Biopharma SRL
2016-12-14 – 2018-09-25 · Chronic Plaque Psoriasis
What this study did
NCT03025542 · UCB Biopharma SRL
2016-12-27 – 2017-12-11 · Chronic Plaque Psoriasis
What this study did
NCT02905006 · UCB Biopharma S.P.R.L.
2016-08 – 2017-07 · Chronic Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT03347110 · UCB Biopharma SRL
2017-11-22 – 2020-10-29 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT07767864 · Oregon Health and Science University
2026-09-01 – 2028-09 · Pyoderma Gangrenosum
What this study did
NCT03355573 · UCB Biopharma SRL
2017-11-28 – 2022-10-19 · Ankylosing Spondylitis
What this study did
NCT03215277 · UCB Biopharma SRL
2017-10-04 – 2020-05-25 · Ankylosing Spondylitis
What this study did
NCT02963506 · UCB Biopharma S.P.R.L.
2016-10 – 2018-08 · Ankylosing Spondylitis
What this study did
NCT02430909 · UCB Celltech
2015-04 – 2017-04 · Rheumatoid Arthritis
What this study did
Phase 1 (9)
Hidradenitis Suppurativa
NCT06888193 · UCB Biopharma SRL
2025-11-05 – 2027-12-31 · Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
What this study did
Psoriasis
NCT02529956 · UCB Celltech
2012-11 – 2014-01 · Mild to Moderate Psoriasis
What this study did
Psoriatic Arthritis
NCT07290036 · UCB Biopharma SRL
2025-12-10 – 2028-09-14 · Psoriatic Arthritis, Axial Spondyloarthritis
What this study did
NCT02141763 · UCB Celltech
2014-05 – 2015-08 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT05292131 · UCB Biopharma SRL
2022-03-17 – 2023-01-09 · Healthy Study Participants
What this study did
NCT04255862 · UCB Biopharma SRL
2020-02-12 – 2021-04-26 · Healthy Study Participants
What this study did
NCT03895385 · UCB Biopharma S.P.R.L.
2019-04-02 – 2019-10-04 · Healthy Volunteers
What this study did
NCT03707717 · UCB Biopharma S.P.R.L.
2018-10-15 – 2019-06-05 · Healthy Volunteers
What this study did
NCT05028127 · UCB Celltech
2016-03-04 – 2016-06-17 · Healthy Volunteers
What this study did
Phase 4 (5)
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT06336343 · Icahn School of Medicine at Mount Sinai
2024-06-03 – 2026-03-17 · Plaque Psoriasis
What this study did
NCT04340076 · Radboud University Medical Center
2020-08-20 – 2025-01-31 · Psoriasis, Psoriasis Vulgaris
What this study did
Psoriatic Arthritis
NCT05499416 · Innovaderm Research Inc.
2023-01 – 2024-04 · Psoriasis Vulgaris, Active Psoriatic Arthritis
What this study did
Other / comorbidity
NCT07497620 · Mayo Clinic
2026-10-01 – 2027-12-01 · Pityriasis Rubra Pilaris
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (2)
Hidradenitis Suppurativa
NCT07766005 · Spyre Therapeutics, Inc.
2026-10-06 – 2028-06 · Hidradenitis Suppurativa (HS)
What this study did
Other / comorbidity
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Hidradenitis Suppurativa: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Bimekizumab (Bimzelx): this drugApprovedMonoclonal antibodyIL-17A/FPartial signal
NCT04242498: HiSCR50 at week 16: bimekizumab dosing regimen 1 53.8% (n=144) and regimen 2 52.0% (n=291) vs placebo 32.2% (n=74); odds ratios 2.42 (95% CI 1.22 to 4.80), p=0.004, and 2.29 (95% CI 1.22 to 4.29), p=0.003 (CT.gov posted results).
NCT04242446: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 (Week 16): Placebo 28.7 percentage of participants (95% CI 18.1 to 39.3) | BKZ Dosing Regimen 1 45.3 percentage of participants (95% CI 36.8 to 53.8) | BKZ Dosing Regimen 2 47.8 percentage of participants (95% CI 41.8 to 53.7)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Secukinumab (Cosentyx)ApprovedMonoclonal antibodyIL-17Partial signal
NCT03713632: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): AIN457 Q2W 42.3 Percentage of Participants | AIN457 Q4W 46.1 Percentage of Participants | Placebo 31.2 Percentage of Participants
NCT03713619: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): Secukinumab 1 - Q2W 45 Percentage of participants | Secukinumab 2 - Q4W 41.8 Percentage of participants | Placebo 33.7 Percentage of participants
LutikizumabPhase 3Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
RemibrutinibPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
Ruxolitinib (Opzelura)Phase 3Small moleculeJAK1/2not yet gradedNo reviewed efficacy summary in this indication
SonelokimabPhase 3Antibody-derived scaffoldIL-17A/Fnot yet gradedNo reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)Phase 3Small moleculeJAK, JAK1not yet gradedNo reviewed efficacy summary in this indication
BFB759Phase 2/3Monoclonal antibodyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
Spesolimab (Spevigo)Phase 2/3Monoclonal antibodyIL-36 receptornot yet gradedNo reviewed efficacy summary in this indication
AbdakibartPhase 2Monoclonal antibodyIL-1 betanot yet gradedNo reviewed efficacy summary in this indication
DuvakitugPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
EltrekibartPhase 2Monoclonal antibodyCXCR1/2not yet gradedNo reviewed efficacy summary in this indication
OlatorepatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ORKA-002Phase 2Monoclonal antibodyIL-17A/Fnot yet gradedNo reviewed efficacy summary in this indication
SAR442970Phase 2——not yet gradedNo reviewed efficacy summary in this indication
SAR445399Phase 2Monoclonal antibodyIL-1R3 (IL1RAP)not yet gradedNo reviewed efficacy summary in this indication
SPY072Phase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
ZasocitinibPhase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ABBV-1451
Phase 1(overall)
UndisclosedIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
SAR447971
Phase 1(overall)
Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
TipasertidegDiscontinuedSmall moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Bimzelx (bimekizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3Hidradenitis SuppurativaActive not recruiting
Est. primary completion 2026-12-21 · NCT06921850 · CT.gov ↗
What to watch
2027 (4)
March 2027 (1)
Phase 3PsoriasisActive not recruiting
Est. primary completion 2027-03-09 · NCT06506916 · CT.gov ↗
What to watch
October 2027 (1)
Phase 4Pityriasis Rubra PilarisNot yet recruiting
Est. primary completion 2027-10-01 · NCT07497620 · CT.gov ↗
What to watch
December 2027 (2)
Phase 3Palmoplantar PustulosisRecruiting
Est. primary completion 2027-12-27 · NCT07219420 · CT.gov ↗
What to watch
Phase 1PsoriasisRecruiting
Est. primary completion 2027-12-31 · NCT06888193 · CT.gov ↗
What to watch
2028 (5)
April 2028 (1)
Phase 3Psoriatic ArthritisRecruiting
Est. primary completion 2028-04-12 · NCT06668181 · CT.gov ↗
What to watch
May 2028 (1)
Phase 1Psoriatic ArthritisRecruiting
Est. primary completion 2028-05-18 · NCT07290036 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Pyoderma GangrenosumNot yet recruiting
Est. primary completion 2028-06 · NCT07767864 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2PsoriasisRecruiting
Est. primary completion 2028-07-22 · NCT06742333 · CT.gov ↗
What to watch
August 2028 (1)
Phase 3PsoriasisActive not recruiting
Est. primary completion 2028-08-21 · NCT06425549 · CT.gov ↗
What to watch
2030 (2)
April 2030 (1)
Phase 3PsoriasisNot yet recruiting
Est. primary completion 2030-04-15 · NCT07836283 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 November 2024ApprovalFDA approves BIMZELX for moderate-to-severe hidradenitis suppurativa
US, FDA · Source ↗